Business
Median Technologies Receives €19 Million From the European Investment Bank, Corresponding to the First Tranche Under the 2025 Loan Facility
SOPHIA ANTIPOLIS, France, October 21, 2025--Regulatory News: Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible, "Median" or the "Company"), manufacturer of eyonis®, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnosis, and a globally leading provider of AI-based image analyses and central imaging services for oncology drug developers, announced today the receipt of a €19 million payment under the first tranche of the finan
About this update from Median Technologies
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1240,"height":461,"url":"https://media.zenfs.com/en/business-wire.com/9400bb778181acb56de8940607cafe0e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/pbuhjFSPGoC_9K2ldcSOaw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM1NztjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/9400bb778181acb56de8940607cafe0e","width":960,"height":357},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/7VbyDwUeRwFvHOluN1x_3A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD04OTI7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/9400bb778181acb56de8940607cafe0e","width":1200,"height":446}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Proceeds to support the commercial launch of eyonis® LCS in the U.S. and Europe, and accelerate the broader development of eyonis®, Median’s AI-powered Software as a Medical Device suite for early cancer diagnosis","length":213,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"€20.7 million repayment of the first tranche of the 2019 EIB loan facility completed on October 17, 2025","length":104,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Following these transactions, the Company’s cash runway is extended through Q4 2026","length":83,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":400,"olType":false},{"type":"text","content":"SOPHIA ANTIPOLIS, France, October 21, 2025--(BUSINESS WIRE)--Regulatory News:","length":77,"tagName":"p"},{"type":"text","content":"Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible, "Median" or the "Company"), manufacturer of eyonis®, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnosis, and a globally leading provider of AI-based image analyses and central imaging services for oncology drug developers, announced today the receipt of a €19 million payment under the first tranche of the financial agreement executed with the European Investment Bank (EIB) on July 11, 2025, which has a total value of up to €37.5 million.","length":588,"tagName":"p"},{"type":"text","content":"Fredrik Brag, CEO and Founder of Median Technologies, stated: "We have been collaborating with the European Investment B...